% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • kmaggon kmaggon Jan 2, 2011 3:31 AM Flag

    A new mab for diabetes

    Gevokizumab (Xoma 052) Review
    In anticipation of positive Phase II data in the 1Q2011 and a potential billion dollar licensing deal with big pharma for diabetes, an interactive multimedia review provides history of Xoma, preclinical and clinical data and Net portfolio value of the mab Xoma 052. Can be accessed by smart phones and mobile devices by the QR code:

38.67+0.52(+1.36%)Sep 28 4:03 PMEDT